You are here: Industry Insights > European

News List

Deloitte finds Pharma returns on R&D reach new low europeanpharmaceuticalreview
April 16, 2019
Deloitte finds Pharma returns on R&D reach new low.
EMA restricts use of multiple sclerosis medicine, Lemtrada europeanpharmaceuticalreview
April 16, 2019
EMA restricts use of multiple sclerosis medicine, Lemtrada.
Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries firstwordpharma
April 12, 2019
Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative...
Positive Scientific Advice from European Medicines Agency for Chronocort firstwordpharma
April 12, 2019
European Medicines Agency confirms the current clinical and regulatory path for Chronocort®...
ESMO drives EU-level action to tackle shortages of essential medicines europeanpharmaceuticalreview
April 12, 2019
Shortages of inexpensive, essential medicines: calling for tangible political commitments in the EU…
Alvogen, Business Partners Obtain First European Approvals for Generic Ulipristal 5mg americanpharmaceuticalreview
April 11, 2019
Alvogen, Business Partners Obtain First European Approvals for Generic Ulipristal 5mg.
European approval for Teva’s migraine drug Ajovy pharmatimes
April 02, 2019
Teva has received European Commission approval for its migraine drug, Ajovy (fremanezumab). The drug is a pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.
European Commission Approves Ipsen’s Cabometyx® for Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib americanpharmaceuticalreview
November 19, 2018
Ipsen announced that the European Commission (EC) has approved Cabometyx (cabozantinib) 20, 40, 60 mg as a monotherapy f
uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) biospectrumasia
October 17, 2018
Press Release AMT-060 uniQure Haemophilia Clinical Research (R&D) Medical Affairs ESGCT
AstraZeneca divests Atacand’s European rights for $210m pharmaceutical-technology
July 27, 2018
AstraZeneca has signed an agreement to sell the European commercial rights for its Atacand (candesartan cilexetil) drug to German pharmaceutical company Cheplapharm Arzneimittel for $200m.

Previous page 1 2 3 Next page